http://www.zibb.com/all/theme/cq/Savient+Pharmaceuticals+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Wed, 28 Oct 2009 22:32:00 GMTWed, 28 Oct 2009 22:32:00 GMT608831http://www.zibb.com/all/theme/cq/Savient+Pharmaceuticals+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.prnewswire.com/news-releases/savient-pharmaceuticals-to-hold-third-quarter-2009-financial-results-conference-call-on-thursday-november-5-2009-67049882.htmlSavient Pharmaceuticals to Hold Third Quarter 2009 Financial Results Conference Call on Thursday, November 5, 2009.http://www.prnewswire.com/news-releases/savient-pharmaceuticals-to-hold-third-quarter-2009-financial-results-conference-call-on-thursday-november-5-2009-67049882.htmlSavient Pharmaceuticals IncorporatedWed, 28 Oct 2009 22:32:00 GMThttp://www.zibb.com/article/5625794/Savient+Pharmaceuticals+to+Hold+Third+Quarter+Financial+Results+Conference+Call+on+Thursday+NovemberEAST BRUNSWICK, N.J., Oct. 28 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the third quarter 2009 following the close of the market on Wednesday, November 4, 2009. Paul Hamelin, President and David Gionco, Group Vice President andhttp://www.zibb.com/article/5625794/Savient+Pharmaceuticals+to+Hold+Third+Quarter+Financial+Results+Conference+Call+on+Thursday+NovemberSavient Pharmaceuticals IncorporatedWed, 28 Oct 2009 18:32:00 GMThttp://www.newratings.com/en/main/company_headline.m?id=1947338NEW YORK, August 4 (newratings.com) - Analysts at Jefferies & Co downgrade Savient Pharma (ticker: SVNT) from "hold" to "underperform." The target price is set to $5. [more]http://www.newratings.com/en/main/company_headline.m?id=1947338Savient Pharmaceuticals IncorporatedTue, 04 Aug 2009 16:49:02 GMThttp://www.biospace.com/news_story.aspx?StoryID=146052&full=1EAST BRUNSWICK, N.J., June 16 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. announced today that the Arthritis Advisory Committee appointed by the U.S.http://www.biospace.com/news_story.aspx?StoryID=146052&full=1Savient Pharmaceuticals IncorporatedThu, 18 Jun 2009 12:00:00 GMThttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=2882887&HITNO=9&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=biotechnology%20pharmaceutical&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R%3adate&R=2882887&THISHREF=http%3a//c.moreover.com/click/here.pl%3fz2031942967%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBiotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directoryhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=2882887&HITNO=9&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=biotechnology%20pharmaceutical&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R%3adate&R=2882887&THISHREF=http%3a//c.moreover.com/click/here.pl%3fz2031942967%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSavient Pharmaceuticals IncorporatedMon, 15 Jun 2009 11:30:58 GMThttp://www.fda.gov/cder/ogd/AG_Listing.htmNote: This list of authorized generic drugs (AGs) was created from a manual review of FDA’s database of annual reports submitted to the FDA since January 1, 1999 by sponsors of new drug applications (NDAs).http://www.fda.gov/cder/ogd/AG_Listing.htmSavient Pharmaceuticals IncorporatedFri, 27 Mar 2009 11:40:00 GMThttp://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20081230005409&newsLang=enCINCINNATI--(BUSINESS WIRE)--Option traders are honing in on Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today, and these speculative investors are displaying a distinct preference for puts. So far, the equity'shttp://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20081230005409&newsLang=enSavient Pharmaceuticals IncorporatedTue, 30 Dec 2008 19:44:00 GMThttp://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/12-08-2008/0004938154&EDATE=Individuals can listen to a live webcast of the presentation by logging on to the Investor Relations section of Savient Pharmaceuticals' web site, http://www.savient.com. A replay of the webcast will be available on the company's web site for 30 days. ABOUT SAVIENT PHARMACEUTICALS, INC.http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/12-08-2008/0004938154&EDATE=Savient Pharmaceuticals IncorporatedMon, 08 Dec 2008 12:30:00 GMThttp://seekingalpha.com/article/104972-amgen-remember-its-biotech-bloodlines?source=feedRyan Barnes submits:Amgen (AMGN) is one of the founding fathers of biopharma, but after showing its age in recent years with slowinghttp://seekingalpha.com/article/104972-amgen-remember-its-biotech-bloodlines?source=feedSavient Pharmaceuticals IncorporatedSun, 09 Nov 2008 14:32:36 GMThttp://us.rd.yahoo.com/finance/external/pssa/rss/SIG=12nuv5fn8/*http://seekingalpha.com/article/103207-comcast-internet-and-tv-more-popular-than-ever?source=yahooComcast (CMCSA) executives say that despite economic conditions (or because of them), people want to watch TV and have access to the internet more than ever. Customers are increasingly ditching their fixed lines for mobile, and Comcast is upbeat on its Wimax prospects.http://us.rd.yahoo.com/finance/external/pssa/rss/SIG=12nuv5fn8/*http://seekingalpha.com/article/103207-comcast-internet-and-tv-more-popular-than-ever?source=yahooSavient Pharmaceuticals IncorporatedFri, 31 Oct 2008 08:46:25 GMThttp://classactiondefense.jmbm.com/2008/07/securities_fraud_class_action_2.htmlDistrict Court did not Err in Dismissing Securities Class Action Without Leave to Amend because Second Amended Class Action Complaint Failed to Adequately Plead Scienter Third Circuit Holds Plaintiff filed a putative class action against Bio-Technology General Corp. (now known ashttp://classactiondefense.jmbm.com/2008/07/securities_fraud_class_action_2.htmlSavient Pharmaceuticals IncorporatedMon, 07 Jul 2008 18:18:53 GMThttp://topics.nytimes.com/top/news/business/companies/savient-pharmaceuticals-inc/index.htmlGet Home Delivery Log In Register Now Home Page My Times Today's Paper Video Most Popular Times Topics Business All NYT New York Times Business World U.S. N.Y. / Region Business Media & Advertising World Business Small Business Your Money DealBook Markets Research Mutual Funds My Portfolio Alertshttp://topics.nytimes.com/top/news/business/companies/savient-pharmaceuticals-inc/index.htmlSavient Pharmaceuticals Incorporatedhttp://www.packagingtoday.co.uk/story.asp?storycode=42193US speciality pharmaceutical company Savient Pharmaceuticals has completed the sale of its wholly owned UK-based subsidiary, Rosemont Pharmaceuticals, to an entity affiliated with Close Brothers Private Equity for US$176m.http://www.packagingtoday.co.uk/story.asp?storycode=42193Savient Pharmaceuticals Incorporatedhttp://www.holdrs.com/holdrs/main/index.asp?Action=Article&Description=&Image=&newsid={F5C8B78F-1381-4E39-8846-277E6BF2129C}&symb=SVNT&sid=1487617EAST BRUNSWICK, N.J., Oct 14, 2008 /PRNewswire-FirstCall via COMTEX/ -- Savient Pharmaceuticals, Inc. (NASDAQ GM:SVNT) , announced today that the Company's Chief Medical Officer, Dr.http://www.holdrs.com/holdrs/main/index.asp?Action=Article&Description=&Image=&newsid={F5C8B78F-1381-4E39-8846-277E6BF2129C}&symb=SVNT&sid=1487617Savient Pharmaceuticals Incorporatedhttp://www.zibb.com/article/5621645/Savient+Pharmaceuticals+to+Present+at+the+Oppenheimer+th+Annual+Healthcare+ConferenceSavient Pharmaceuticals, Inc. (Nasdaq:SVNT) today announced that Paul Hamelin, President of Savient Pharmaceuticals will be presenting at the upcoming Oppenheimer 20th Annual Healthcare Conference on November 3rd, 2009. The presentation is scheduled to begin on Tuesday, November 3, 2009 at 1:35http://www.zibb.com/article/5621645/Savient+Pharmaceuticals+to+Present+at+the+Oppenheimer+th+Annual+Healthcare+ConferenceSavient Pharmaceuticals IncorporatedTue, 27 Oct 2009 16:31:15 GMThttp://www.zibb.com/article/5597511/Savient+Pharmaceuticals+Inc+SVNT+Corporate+Event+Announcement+NoticeSavient Pharmaceuticals Inc. (SVNT) Expected next earnings release: Announcement date: 11/4/2009 - After Market Earnings Quarter: Q3 Announcement Status: Unconfirmedhttp://www.zibb.com/article/5597511/Savient+Pharmaceuticals+Inc+SVNT+Corporate+Event+Announcement+NoticeSavient Pharmaceuticals IncorporatedFri, 16 Oct 2009 21:29:48 GMThttp://www.newratings.com/en/main/company_headline.m?id=1927825NEW YORK, June 17 (newratings.com) - Analysts at JMP Securities initiate coverage of Savient Pharma (ticker: SVNT) with a "market outperform" rating. The target price is set to $15. [more]http://www.newratings.com/en/main/company_headline.m?id=1927825Savient Pharmaceuticals IncorporatedThu, 18 Jun 2009 03:44:25 GMThttp://www.biospace.com/news_story.aspx?StoryID=137790&full=1EAST BRUNSWICK, N.J., May 1, 2009 (GLOBE NEWSWIRE) -- Savient Pharmaceuticals, Inc. (NasdaqGM:SVNT - News) today announced that Paul Hamelin, President of Savient Pharmaceuticals, will be presenting at the upcoming Bank of America and Merrill Lynch 2009 Health Care Conference.http://www.biospace.com/news_story.aspx?StoryID=137790&full=1Savient Pharmaceuticals IncorporatedFri, 01 May 2009 12:00:00 GMThttp://www.zibb.com/article/5596553/Savient+Pharmaceuticals+raises+million+through+public+offering+of+common+stockSavient Pharmaceuticals, Inc., a US-based specialty biopharmaceutical company, has raised $65.72 million through a public offering of common stock. Including the over-allotment option which was exercised in full by the underwriters, the company sold a total of 4.945 million shares of its commonhttp://www.zibb.com/article/5596553/Savient+Pharmaceuticals+raises+million+through+public+offering+of+common+stockSavient Pharmaceuticals IncorporatedFri, 16 Oct 2009 14:29:18 GMThttp://www.zibb.com/article/5593142/Savient+Pharmaceuticals+Announces+Closing+of+Public+Offering+and+Exercise+of+Over+Allotment+OptionSavient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 645,000 shares of common stock. As a result, Savient sold a total ofhttp://www.zibb.com/article/5593142/Savient+Pharmaceuticals+Announces+Closing+of+Public+Offering+and+Exercise+of+Over+Allotment+OptionSavient Pharmaceuticals IncorporatedThu, 15 Oct 2009 11:22:00 GMThttp://seekingalpha.com/article/104880-boning-up-on-amgen-s-d-mab-for-osteoporosis?source=feedMike Huckman submits: While on the elliptical at the gym the other night I was watching one network newscast and the person on the machine next to me was watching another one. Both shows hit their commercial breakshttp://seekingalpha.com/article/104880-boning-up-on-amgen-s-d-mab-for-osteoporosis?source=feedSavient Pharmaceuticals IncorporatedSun, 09 Nov 2008 07:30:23 GMThttp://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/10-24-2008/0004911211&EDATE=EAST BRUNSWICK, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the third quarter 2008 following the close of the market on Wednesday, November 5, 2008.http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/10-24-2008/0004911211&EDATE=Savient Pharmaceuticals IncorporatedFri, 24 Oct 2008 20:05:00 GMThttp://us.rd.yahoo.com/finance/external/pssa/rss/SIG=120kuf1pr/*http://seekingalpha.com/article/100741-earnings-preview-pfizer?source=yahooAnalysts are looking for a profit of 60c on revenue of $12B. The consensus range is 55c to 63c for EPS, and revenue of $11.53B to $12.34B, according to First Call.http://us.rd.yahoo.com/finance/external/pssa/rss/SIG=120kuf1pr/*http://seekingalpha.com/article/100741-earnings-preview-pfizer?source=yahooSavient Pharmaceuticals IncorporatedMon, 20 Oct 2008 17:45:37 GMThttp://www.zibb.com/article/5498197/Savient+Pharmaceuticals+SVNT+Bullish+Technical+Alert+Trend+UpSavient Pharmaceuticals (NASDAQ:SVNT) is trading 4.4% higher (up $0.61 to $14.50) today on volume of 311,723 shares. The stock has traded within a 52-week range of $2.80 and $23.01. Savient Pharmaceuticals is currently above its 50-day moving average of $13.57 and above its 200-day moving averagehttp://www.zibb.com/article/5498197/Savient+Pharmaceuticals+SVNT+Bullish+Technical+Alert+Trend+UpSavient Pharmaceuticals IncorporatedTue, 01 Sep 2009 11:29:00 GMThttp://www.zibb.com/article/5597978/Savient+Pharmaceuticals+Inc+SVNT+Corporate+Event+Announcement+NoticeSavient Pharmaceuticals Inc. (SVNT) Expected next earnings release: Announcement date: 11/4/2009 - After Market Earnings Quarter: Q3 Announcement Status: Unconfirmedhttp://www.zibb.com/article/5597978/Savient+Pharmaceuticals+Inc+SVNT+Corporate+Event+Announcement+NoticeSavient Pharmaceuticals IncorporatedSat, 17 Oct 2009 21:01:27 GMT